NOVARTIS N (NOT MU) stock market data APIs
€129.4663
0.07(0.1%)
as of March 20, 2026
Try our APIs with
free plan!
NOVARTIS N Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.MU.
Prev. Close
129.4663
Open
129.5403
High
129.7883
Low
129.405
52 wk Range
72.8564-139.1148
Market Cap
160 075 M
Dividends (Yield)
0.0488
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N data using free add-ons & libraries
Get NOVARTIS N Fundamental Data
NOVARTIS N Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N News
New
Stocks to Watch Recap: Super Micro Computer, FedEx, Unilever
↗️ FedEx (FDX): The shipping company raised its outlook as revenue increased in the fiscal third quarter. Shares rose 0.8%. ↘️ Super Micro Computer (SMCI): The technology company placed two em...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
Novartis NVS is doubling down on precision oncology with a targeted bolt-on acquisition that strengthens its position in one of the largest segments of breast cancer. Novartis has agreed to acquire a...
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with active psoriatic arthritis (PsA). The decision adds a second major indicati...
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
This article first appeared on GuruFocus. Novartis (NYSE:NVS) is doubling down on oncology at a moment when its existing breast cancer franchise is starting to face pressure, agreeing to acquire an e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
